S&P 500   5,253.78 (+0.10%)
DOW   39,783.69 (+0.06%)
QQQ   444.47 (-0.08%)
AAPL   170.83 (-1.43%)
MSFT   420.79 (-0.15%)
META   487.78 (-1.23%)
GOOGL   150.37 (-0.33%)
AMZN   180.31 (+0.27%)
TSLA   176.56 (-1.82%)
NVDA   907.69 (+0.58%)
NIO   4.63 (-0.86%)
AMD   181.34 (+0.97%)
BABA   72.52 (+1.30%)
T   17.58 (+0.17%)
F   13.27 (+1.61%)
MU   118.57 (-0.48%)
CGC   9.55 (+0.00%)
GE   175.46 (-2.59%)
DIS   123.02 (+1.69%)
AMC   3.70 (-14.75%)
PFE   27.87 (+0.32%)
PYPL   66.80 (+0.35%)
XOM   115.64 (+0.58%)
S&P 500   5,253.78 (+0.10%)
DOW   39,783.69 (+0.06%)
QQQ   444.47 (-0.08%)
AAPL   170.83 (-1.43%)
MSFT   420.79 (-0.15%)
META   487.78 (-1.23%)
GOOGL   150.37 (-0.33%)
AMZN   180.31 (+0.27%)
TSLA   176.56 (-1.82%)
NVDA   907.69 (+0.58%)
NIO   4.63 (-0.86%)
AMD   181.34 (+0.97%)
BABA   72.52 (+1.30%)
T   17.58 (+0.17%)
F   13.27 (+1.61%)
MU   118.57 (-0.48%)
CGC   9.55 (+0.00%)
GE   175.46 (-2.59%)
DIS   123.02 (+1.69%)
AMC   3.70 (-14.75%)
PFE   27.87 (+0.32%)
PYPL   66.80 (+0.35%)
XOM   115.64 (+0.58%)
S&P 500   5,253.78 (+0.10%)
DOW   39,783.69 (+0.06%)
QQQ   444.47 (-0.08%)
AAPL   170.83 (-1.43%)
MSFT   420.79 (-0.15%)
META   487.78 (-1.23%)
GOOGL   150.37 (-0.33%)
AMZN   180.31 (+0.27%)
TSLA   176.56 (-1.82%)
NVDA   907.69 (+0.58%)
NIO   4.63 (-0.86%)
AMD   181.34 (+0.97%)
BABA   72.52 (+1.30%)
T   17.58 (+0.17%)
F   13.27 (+1.61%)
MU   118.57 (-0.48%)
CGC   9.55 (+0.00%)
GE   175.46 (-2.59%)
DIS   123.02 (+1.69%)
AMC   3.70 (-14.75%)
PFE   27.87 (+0.32%)
PYPL   66.80 (+0.35%)
XOM   115.64 (+0.58%)
S&P 500   5,253.78 (+0.10%)
DOW   39,783.69 (+0.06%)
QQQ   444.47 (-0.08%)
AAPL   170.83 (-1.43%)
MSFT   420.79 (-0.15%)
META   487.78 (-1.23%)
GOOGL   150.37 (-0.33%)
AMZN   180.31 (+0.27%)
TSLA   176.56 (-1.82%)
NVDA   907.69 (+0.58%)
NIO   4.63 (-0.86%)
AMD   181.34 (+0.97%)
BABA   72.52 (+1.30%)
T   17.58 (+0.17%)
F   13.27 (+1.61%)
MU   118.57 (-0.48%)
CGC   9.55 (+0.00%)
GE   175.46 (-2.59%)
DIS   123.02 (+1.69%)
AMC   3.70 (-14.75%)
PFE   27.87 (+0.32%)
PYPL   66.80 (+0.35%)
XOM   115.64 (+0.58%)
NASDAQ:YMTX

Yumanity Therapeutics (YMTX) Stock Price, News & Analysis

$0.52
-0.03 (-5.44%)
(As of 03/27/2024 ET)
Today's Range
$0.51
$0.60
50-Day Range
$0.52
$2.83
52-Week Range
$0.95
$13.23
Volume
99,011 shs
Average Volume
473,083 shs
Market Capitalization
$5.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
YMTX stock logo

About Yumanity Therapeutics Stock (NASDAQ:YMTX)

Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein. The company is also developing YTX-9184, which is in preclinical studies to treat neurological disorders. Yumanity Therapeutics Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

YMTX Stock Price History

YMTX Stock News Headlines

JSPR Jasper Therapeutics, Inc.
Cara Therapeutics Inc CARA
A lot of people are making this costly mistake
You may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time.
Yumanity Therapeutics Inc.
This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
Why Is Yumanity Therapeutics (YMTX) Stock Up Today?
See More Headlines
Receive YMTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Yumanity Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/12/2021
Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:YMTX
Fax
N/A
Employees
40
Year Founded
N/A

Profitability

Net Income
$-39,500,000.00
Net Margins
-660.61%
Pretax Margin
-660.61%

Debt

Sales & Book Value

Annual Sales
$4.84 million
Book Value
$2.28 per share

Miscellaneous

Free Float
9,504,000
Market Cap
$5.66 million
Optionable
Not Optionable
Beta
0.32
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Richard Peters M.D. (Age 59)
    Ph.D., CEO, Pres & Director
    Comp: $896.1k
  • Dr. Vikram Khurana M.D.
    Ph.D., Scientific Co-Founder & Sr. Advisor of Discovery Biology
  • Ms. Chee Yeun Chung Ph.D.
    Scientific Co-Founder & Associate Director of Discovery Biology
  • Ms. Marie Epstein CPA
    VP of Fin.
  • Mr. Michael D. Wyzga (Age 33)
    SVP, CFO & Treasurer
  • Mr. Devin Whittemore Smith (Age 54)
    SVP, Gen. Counsel & Sec.

YMTX Stock Analysis - Frequently Asked Questions

How have YMTX shares performed in 2024?

Yumanity Therapeutics' stock was trading at $3.63 at the start of the year. Since then, YMTX stock has decreased by 85.6% and is now trading at $0.5213.
View the best growth stocks for 2024 here
.

How were Yumanity Therapeutics' earnings last quarter?

Yumanity Therapeutics, Inc. (NASDAQ:YMTX) announced its earnings results on Thursday, August, 12th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by $0.19. The firm earned $2.11 million during the quarter, compared to the consensus estimate of $2.27 million. Yumanity Therapeutics had a negative net margin of 660.61% and a negative trailing twelve-month return on equity of 263.34%.

How do I buy shares of Yumanity Therapeutics?

Shares of YMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:YMTX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners